Edition:
United States

Sumitomo Dainippon Pharma Co Ltd (4506.T)

4506.T on Tokyo Stock Exchange

1,925JPY
9:44pm EDT
Change (% chg)

¥-35 (-1.79%)
Prev Close
¥1,960
Open
¥1,956
Day's High
¥1,968
Day's Low
¥1,919
Volume
739,700
Avg. Vol
1,289,475
52-wk High
¥2,028
52-wk Low
¥1,132

Latest Key Developments (Source: Significant Developments)

Cynapsus says Sunovion Pharma entitled to termination fee of $24 mln if deal terminated - SEC filing
Thursday, 1 Sep 2016 07:31am EDT 

Cynapsus Therapeutics : Sunovion Pharma entitled to termination fee in amount of $24 million which shall be paid by co if deal terminated - SEC filing Source: (http://bit.ly/2bT5Y0k ) Further company coverage: [CTH.TO] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Sumitomo Dainippon Pharma to offer early-retirement program
Tuesday, 30 Aug 2016 03:25am EDT 

Sumitomo Dainippon Pharma Co Ltd <4506.T>: Says it to offer an early-retirement program to employees, who are above 45 years old as of Nov. 30 and worked more than five years (except part of employees) . Says offering period from Sep. 26 to Oct. 14 . Says the employees who take up the offer will retire on Nov. 30 .Says a premium will be added to the normal retirement payment, and the company will provide re-employment support to the retiring employees.  Full Article

Boston Biomedical announces first orphan drug designation for Napabucasin in gastric/gej cancer
Thursday, 23 Jun 2016 12:13pm EDT 

Boston Biomedical : Boston Biomedical announces first orphan drug designation for Napabucasin in gastric/gej cancer .Boston Biomedical - Napabucasin currently investigated in a phase iii clinical trial in combination with paclitaxel in patients with advanced gastric and gej cancer.  Full Article

Sumitomo Dainippon Pharma unit says positive results from two phase 3 clinical studies
Wednesday, 27 Apr 2016 07:40pm EDT 

Sumitomo Dainippon Pharma Co., Ltd:Subsidiary Sunovion Pharmaceuticals Inc announced positive results from the Phase 3 clinical trial program for SUN-101 (glycopyrrolate).SUN-101 that a nebulized long-acting muscarinic antagonist (LAMA), delivered via PARI’s innovative investigational eFlow® nebulizer system (SUN-101/eFlow® ), for people with moderate-to-very severe chronic obstructive pulmonary disease (COPD.The two clinical trials met their primary endpoints with a statistically significant change from baseline in trough forced expiratory volume in one second (FEV1) at Week 12 for both the 50 mcg and 25 mcg dose groups versus placebo.SUN-101/eFlow® also was found to be well-tolerated as a twice-daily maintenance treatment of bronchoconstriction in patients with COPD.  Full Article

Sumitomo Dainippon Pharma raises consolidated full-year outlook for FY 2016
Wednesday, 27 Jan 2016 01:00am EST 

Sumitomo Dainippon Pharma Co., Ltd:Says the consolidated full-year outlook for revenue is 403 billion yen (2 billion yen increased) for FY ending March 2016.Operating profit forecast is 33 billion yen (4 billion yen increased).Ordinary profit forecast is 32.5 billion yen (4 billion yen increased).Net profit forecast is 23 billion yen (3 billion yen increased).  Full Article

Sumitomo Dainippon Pharma raises consolidated mid-year outlook for FY 2016
Friday, 23 Oct 2015 12:00am EDT 

Sumitomo Dainippon Pharma Co., Ltd:Says the company raised the consolidated mid-year outlook for the FY ending March 2016.Revenue forecast increased to 198,900 million yen from 197,500 million yen.Operating profit forecast increased to 16,800 million yen from 11,000 million yen.Ordinary profit forecast increased to 17,500 million yen from 11,000 million yen.Net profit forecast increased to 13,200 million yen from 8,000 million yen.Earnings per share forecast increased to 33.22 yen from 20.14 yen.Comments the decreased expense is the main reason for the forecast.  Full Article

Sumitomo Dainippon Pharma revises consolidated mid-year and full-year outlook for FY 2016
Wednesday, 29 Jul 2015 02:00am EDT 

Sumitomo Dainippon Pharma Co., Ltd:Says the company increased the consolidated mid-year outlook for revenue to 197.5 billion yen from 193 million yen for FY ending March 2016.Operating profit forecast remained at 11 billion yen.Ordinary profit forecast remained at 11 billion yen.Net profit forecast remained at 8 billion yen.Says the company increased the consolidated full-year outlook for revenue to 401 billion yen from 392 million yen for FY ending March 2016.Operating profit forecast remained at 27 billion yen.Ordinary profit forecast remained at 26.5 billion yen.Net profit forecast remained at 18 billion yen.  Full Article

R&I affirms Sumitomo Dainippon Pharma's rating at "A" and announces stable outlook
Thursday, 16 Jul 2015 02:00am EDT 

Sumitomo Dainippon Pharma Co., Ltd:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A".Rating outlook stable.  Full Article

Sumitomo Dainippon Pharma and JCR Pharmaceuticals conclude a feasibility study agreement on application of the blood-brain barrier penetration technology in psychiatry and neurology area
Wednesday, 17 Jun 2015 03:00am EDT 

Sumitomo Dainippon Pharma Co., Ltd and JCR Pharmaceuticals Co Ltd:JCR Pharmaceuticals (“JCR”) and Sumitomo Dainippon Pharma executed on June 17 a feasibility study agreement.Under which they will study the feasibility of applying JCR’s proprietary blood-brain barrier penetration technology “J-Brain Cargo” to discovery of new treatment in the psychiatry and neurology area.Under the terms of the agreement, JCR and Sumitomo Dainippon Pharma will perform collaborative research using the J-Brain Cargo technology and certain pharmaceutical candidate compounds of Sumitomo Dainippon Pharma’s choice.With a view to creating innovative pharmaceutical products in psychiatry and neurology area, where high unmet medical needs exist.  Full Article

Dainippon Sumitomo Pharma Co Ltd and Takeda Pharmaceutical Company Ltd announce decision to terminate agreement
Thursday, 7 May 2015 02:00am EDT 

Dainippon Sumitomo Pharma Co Ltd and Takeda Pharmaceutical Company Ltd:Says their license agreement entered into in March 2011 (agreement) will be terminated.Says companies are starting discussions in an effort to finalize and execute a mutual agreement establishing a transition plan for orderly transfer of all development and commercialization rights and activities with respect to Latuda to Sumitomo Dainippon Pharma.Says agreement entered For joint development and exclusive commercialization of pharmaceutical products containing lurasidone hydrochloride (Latuda), an atypical antipsychotic agent, in Europe.Takeda's right to develop and commercialize Latuda within 26 member states of the European Union (excluding U.K), Switzerland, Norway, Turkey and Russia, will transfer back to Sumitomo Dainippon Pharma upon effective date of termination.  Full Article

BRIEF-Sumitomo Dainippon readying new type of cancer treatment for release in fiscal 2017 - Nikkei

* Sumitomo Dainippon Pharma is readying new type of cancer treatment that targets culprit behind metastasis,recurrence for release in fiscal 2017-Nikkei